Navigation Links
PhRMA Honors Patient Advocates Ron and Raychel Bartek

WASHINGTON, March 18 /PRNewswire-USNewswire/ -- Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin today honored Ron and Raychel Bartek for their dedicated work driving awareness of Friedreich's ataxia, a debilitating, life-threatening, rare disease.

The Barteks are co-founders of the Friedreich's Ataxia Research Alliance, an organization dedicated to the pursuit of scientific research leading to treatments and a cure for the disease. However, they are more than advocates; they are also parents of Keith Bartek, who succumbed to Friedreich's ataxia recently at the age of 24.

Although there remains no approved medication to treat the disease, clinical studies are currently being conducted. However, such near-term hope was not always the case, as Raychel Bartek said: "When Keith was diagnosed, I asked the doctor what medicine she would prescribe for him. Her eyes were watering when she said, 'There's nothing he can take.'"

Regarding the lack of treatment options, Ron Bartek added, "The prognosis was awful for Keith."

Unfortunately, millions of families have experienced the same frightening diagnosis of a rare disease that doesn't have any known treatments. In fact, there are more than 1,200 recognized rare diseases, defined as those that affect less than 200,000 people in the U.S. According to the National Organization for Rare Diseases (NORD), roughly 25 million Americans suffer from such a condition.

Like his parents, Keith dedicated his life to raising awareness of the disease, hoping to drive research. "He may have only lived 24 years, but in those 24 years he inspired a lot of people to do the right thing and to accelerate research," Raychel Bartek explained. "Twenty-four years isn't a lot of time for any of us, but he had a purpose in his life and he knew that when he died."

"Because of the relatively small number of patients affected by these rare diseases, many have been historically under-treated," said PhRMA's Tauzin. "That's why America's pharmaceutical research and biotechnology companies continue their commitment to patients suffering from these so-called 'orphan diseases,' and much of that commitment has been facilitated by the Orphan Drug Act."

The Orphan Drug Act provides seven years of market exclusivity to medicines approved to treat a rare disease. Since its passage, the act has spurred increased research for under-treated patients. According to a recent report by the Tufts University Center for the Study of Drug Development, the 425 orphan drug designations for products in development between 2006 and 2008 represent more than twice the number of designations -- 208 -- for the period from 2000 to 2002.

The illnesses being targeted by current rare disease research include rare cancers, autoimmune disorders and cardiovascular disorders. According to a PhRMA survey, some examples of medicines being developed for rare diseases are: a monoclonal antibody for chronic sarcoidosis, an immune system disorder; a medicine for Lennox-Gastaut syndrome, a severe form of epilepsy; a gene therapy for cystic fibrosis; and a medicine for Friedreich's ataxia.

In fact, a 2006 report released by PhRMA and NORD found that more than 160 new medicines for these illnesses had been approved in the decade between 1995 and 2005, compared with 108 such approvals in the decade prior, and fewer than 10 in the 1970s. Many of the new medicines were the first approved to treat a particular disease.

"This recent progress has given under-treated patients access to treatments they've never had before," Tauzin said. "Looking ahead, we will continue to encourage accelerated research in the field of rare diseases and to provide hope for millions of patients to live happier, healthier, more productive lives."

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $45.8 billion in 2009 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.3 billion in 2009.

PhRMA Internet Address:

For information on stories of hope and survival, visit:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For more information on public health emergencies, visit

For information on the danger of imported drugs, visit:

SOURCE Pharmaceutical Research and Manufacturers of America

Back to top



SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Seven New Biopharmaceutical Research Companies Join PhRMAs Mission to Advance Medical Innovation
2. PhRMA Statement Supporting Fair Incentives for Biologics Innovation
3. PhRMA Statement on Senate Finance Committee Vote
4. HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures
5. Fate Therapeutics iPSC Technology Awarded Top Industry Honors for Small Molecule and Protein Reprogramming Breakthroughs
6. AmeriCares Honors Cardinal Health with Power of Partnership Award
7. Prix Galien USA Honors Innovation in Science and Biotech Industries
8. Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer
9. BIOCOMs 4th Annual DeviceFest Honors Companies
10. March of Dimes Honors Dr. Susan Carlson for Outstanding Work In Maternal-Fetal Nutrition
11. Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ) ... Administration of High Viscosity Drugs" report to ... announced the addition of the "Self Administration ... offering. --> Research and Markets ( ... "Self Administration of High Viscosity Drugs" ...
(Date:11/25/2015)... -- The total global healthcare industry is expected to grow at ... America has the highest projected growth at 12.7%, ... ), is second with growth projected at 11.5%. ... expenditure. In 2013-2014, total government funded healthcare was nearly 68%. ... 41.2% in 2013-2014. In real terms, out of pocket expenditure ...
(Date:11/25/2015)... , Nov. 25, 2015 On Tuesday, ... federal bellwether trial against Wright Medical Technology, Inc. ... their Conserve metal-on-metal hip implant device, awarded $11 ... a two week trial and three days of ... hip device was defectively designed and unreasonably dangerous, ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge Memorial ... in the Waterloo region. Using the Ocean Platform, family physicians can now order ... electronic medical record (EMR) without the need for redundant patient entry or an ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... process, participated in the 61st annual Employee Benefits Conference. The Employee Benefits Conference ... Sunday, November 8th through Wednesday, November 11th, 2015. The conference was held at ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... for all, Water For Empowerment ™ attracts volunteers together who want to ... by empowering women as key stakeholders in the process. The non-profit launched its ...
(Date:11/25/2015)... Las Vegas, NV (PRWEB) , ... November 25, 2015 , ... ... Nevada, invites patients to learn more about hair loss treatment with the Capillus272™ Pro ... women an effective solution for thicker and fuller hair, without the need for surgery, ...
(Date:11/25/2015)... FL (PRWEB) , ... November 25, 2015 , ... ... center, is encouraging people across the country to celebrate their sobriety and show ... people to post “before and after” photos this Thanksgiving with the hashtag #FacesOfGratitude ...
Breaking Medicine News(10 mins):